The rules of sharing of medical information are very stringent as compared to the US and other developed countries, which means Chinese companies have access to far more patient data than their western rivals. The Chinese government is pumping billions into biotech research and development. According to official figures, scientific R&D spending topped USD 291 billion in 2018, just over 2% of gross domestic product, and the government is targeting even higher spending of 2.5% of GDP this year. The Chinese government has introduced a centralised procurement process, known as 4+7 bulk tendering intended to bring down prices for common drugs. This regulatory change has helped the generic drugmakers focus on volume and big companies with advanced research teams chase higher margins. Competitive Landscape The Chinese cold chain market is highly fragmented with Sinotrans, SF Express and Beijing Ershang Group as its leading players in the market.